We are monitoring the impact of COVID-19 & Recession alarm on MEA Schizophrenia Drugs Market Get in touch with us for detailed analysis Know More

Know More

Share on

Middle East and Africa Schizophrenia Drugs Market Research Report – Segmented By Therapeutic Class, Treatment & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 8021
Pages: 145

The size of the Middle East and Africa Schizophrenia Drugs Market was worth USD 0.57 billion in 2022 and estimated to be growing at a CAGR of 2.56%, to reach USD 0.65 billion by 2027. 

The Middle East and Africa region accounted for the lowest share in the global market in 2020 due to weak infrastructure in both regions. However, although the market is still in its nascent stages, it is expected to experience healthy growth during the forecast period. Based on the study carried out and the result formulated by the Psychiatric Association, it was recognized that 1 in 24 mental health patients suffered from serious mental disorders that include disorders like severe psychotics. The sharp increase in the number of people with serious mental disorders increases the burden on the health system, health services, and health service providers. The World Health Organization (WHO) recently estimated that one in four people, or about 25% of the world's population, suffers from mental illness in both the developed and developing world.

The regional governments emphasize creating a satisfactory and reliable level of awareness of mental diseases and associated symptoms. Between 30-40% of mental illnesses in the UAE are linked to schizophrenia, while between 30-40% have bipolar disorder. In the Kingdom of Saudi Arabia, mental disorders are seen as below figures: major depressive disorder (41.78%), followed by anxiety disorders (22.78%), substance-induced psychotic disorder (11.48%), schizophrenia (8.92%), and mental retardation (7.32%). According to physicians, the frequency of diagnosis of schizophrenia in Africa varies from 6 to 61%. The African population has experienced social and cultural alterations which developed into mental pathology.

As a result, leading market players are investing in developing highly effective and safe drugs for treating patients with psychotic illnesses with fewer side effects. In addition, main players are bringing innovative new products to the market, such as injectable drugs, which can reduce the frequency of medication and pill anxiety of taking drugs. All these aforementioned factors boost the market during the forecast period.

However, the increase in drug addiction cases associated with these drugs and the expiration of patents on major drugs are hampering the overall market growth. Additionally, the social stigma associated with a mental disorder may challenge the market.

This research report on the MEA schizophrenia drugs market has been segmented and sub-segmented into the following categories.

By Therapeutic Class:

  • Second generation anti-psychotics
    • Risperdal
    • Invega
    • Zyprexa
    • Geodon
    • Seroquel
    • Latuda
    • Aristada
    • Fanapt
    • Saphris
    • Vraylar
  • Third generation anti-psychotics  
  • Others    

By Treatment:

  • Oral anti-psychotics       
  • Injectable anti-psychotics 

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The Middle Eastern region held the largest market share in the MEA schizophrenia drugs market in 2020 and is expected to continue with this trend during the forecast period. In addition, the growing awareness of mental healthcare awareness in Middle Eastern countries like Saudi Arabia, Qatar, United Arab Emirates, and Bahrain will drive the market demand during the forecast period.

The Saudi Arabia market share will grow attributed to various factors like an increase in depression, stress, and mental illnesses due to increased working hours, disposable income per capita, and the presence of a well-established and technologically advanced health system. On the other hand, as the fastest-growing region, the third-largest market share of the MEA market is held by the UAE. The growth in this region is accounted with a high incidence of chronic and mental illnesses mainly due to the hectic lifestyles, advancing health care, growing awareness, and government involvement in increasing health spending.


Some of the major companies dominating the market by their products and services include Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan, and Pfizer.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Second generation anti-psychotics               











                                5.1.3 Third generation anti-psychotics   

                                5.1.4 Others      

                                5.1.5  Y-o-Y Growth Analysis, By Therapeutic class            

                                5.1.6  Market Attractiveness Analysis, By Therapeutic class          

                                5.1.7  Market Share Analysis, By Therapeutic class           

                5.2 Treatment                  

                                5.2.1 Introduction           

                                5.2.2 Oral anti-psychotics             

                                5.2.3 Injectable anti-psychotics 

                                5.2.4 Y-o-Y Growth Analysis, By Treatment          

                                5.2.5 Market Attractiveness Analysis, By Treatment        

                                5.2.6 Market Share Analysis, By Treatment         

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                       By Geographical Area

                                       By Therapeutic class

                                       By Treatment

                                6.1.4  Market Attractiveness Analysis     

                                       By Geographical Area

                                       By Therapeutic class

                                       By Treatment

                                6.1.5  Market Share Analysis      

                                       By Geographical Area

                                       Therapeutic class

                                       By Treatment

                6.2 Middle-East                                

                6.3 Africa                            

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Johnson & Johnson                 

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 AstraZeneca                               

                8.4 Sumitomo Dainippon                             

                8.5 Eli Lilly                           

                8.6 Alkermes                     

                8.7 Vanda Pharma                          

                8.8 Allergan                       

                8.9 Pfizer                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         


                a) List of Tables                

                b) List of Figures                              

  1. Middle East and Africa Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  2. Middle East and Africa Second generation anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  3. Middle East and Africa Third generation anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  4. Middle East and Africa Others Market, By Region, From 2022 - 2027 (USD Billion)
  5. Middle East and Africa Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
  6. Middle East and Africa Oral anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  7. Middle East and Africa Injectable anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  8. Middle East Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  9. Middle East Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
  10. Africa Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  11. Africa Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports




pdf excel


pdf excel powerbi




What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.

Talk to our analyst and get customised report done according to your research needs


Check if you can avail any discount. Submit your details and our team will get back to you.


Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?

Find it too expensive?

Click for Request Sample